anti-RET antibody product blog
Tags: Antibody; Monoclonal Antibody; RET; anti-RET antibody;
The RET ret (Catalog #MBS850230) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The RET Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s RET can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), ELISA (EIA).WB: 1:500-1:2000
ELISA: 1:10000. Researchers should empirically determine the suitability of the RET ret for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The RET ret product has the following accession number(s) (GI #10862701) (NCBI Accession #NP_065681.1) (Uniprot Accession #P07949). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the RET Antibody with the following immunoassay(s):
Western Blot (WB) (Figure 1. Western blot analysis using RET mouse mAb against truncated RET recombinant protein (1) and RET (aa658-1063)-hIgGFc transfected CHO-K1 cell lysate (2).)
RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cell-surface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung\'s disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.
Immunogen: Purified recombinant fragment of RET (aa896-1063) expressed in E. Coli. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing RET are readily searchable from our website. Different antibodies against the same target such as RET may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Adenocarcinoma, Carcinoma, Medullary, Hirschsprung Disease, Hyperplasia, Multiple Endocrine Neoplasia, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b, Nervous System Diseases, Pheochromocytoma, Thyroid Neoplasms are some of the diseases may be linked to RET Antibody.